



Global Health L i m i t e d

November 14 2024

Ref:- GH/2024-25/EXCH/83

The General Manager
Dept. of Corporate Services
BSE Limited,
P J Towers, Dalal Street,
Mumbai - 400 001

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code: 543654

Symbol: MEDANTA

Sub: Investor Presentation

Dear Sir(s),

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of Investor Presentation for the second quarter and half year ended September 30, 2024 Results.

Kindly take the above on record.




Thanking you,

Yours faithfully

For Global Health Limited

Rahul Ranjan
Company Secretary & Compliance Officer
M. No. A17035

Encl: a/a





GLOBAL HEALTH LIMITED

Dedicated to Life

**INVESTOR
PRESENTATION**

Q2 and H1 FY2025



Contents

01 Q2 and H1 FY2025 Performance Update

02 Medanta: Poised to Deliver Sustainable Growth



03 About Us

01

Q2 and H1 FY2025 Performance Update

Q2 FY2025 performance summary

Delivered highest ever quarterly Revenue and EBITDA



*ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days

Q2 FY2025 performance summary

Strong growth across key performance indicators

- Consolidated Total Income of INR 9,748 million, grew by 12.7% y-o-y and 10.4% on q-o-q basis. The growth was driven by a combination of factors including higher patient volumes, increase in bed occupied days and improvement in realisation
- EBITDA was INR 2,465 million, growth of 5.5% y-o-y and 18.4% q-o-q. EBITDA margins were at 25.3% in Q2 FY25
- Profit After Tax was INR 1,308 million, growth of 4.5% y-o-y and 23.1% q-o-q. PAT margins were 13.4% compared to 14.5% in Q2 FY24
- During the quarter, 52 bed were added at Lucknow and 66 beds at Patna resulting in total bed addition of 118 beds
- Average occupied bed days increased by 9.1% y-o-y, with strong occupancy of 64.3% on increased bed capacity
- In-patients count increased by 8.8% y-o-y; Out-patients count increased by 6.6% y-o-y
- ARPOB marginally grew by 1.9% y-o-y to INR 62,140 in Q2 FY25 due to change in case mix
- Matured hospitals revenue was INR 6,882 million, strong growth of 13.5% y-o-y and 7.8% on q-o-q basis. EBITDA was INR 1,739 million, growth of 12.5% y-o-y and 9.4% on q-o-q basis
- Developing hospitals revenue was INR 2,754 million, growth of 4.2% y-o-y and 16.2% on q-o-q basis. EBITDA was INR 823 million, down by 8.2% y-o-y and strong growth of 41.7% on q-o-q basis
- During the quarter, International Patients Revenue was INR 513 million
- Out-patient pharmacy (Hospital + Retail) continues to register strong growth. Revenue increased by 25% from INR 298 million in Q2 FY24 to INR 371 million in Q2 FY25

Q2 FY2025 business update

Continued focus on strengthening the core



Capacity Expansion

- ✓ **118 Total Beds including 92 census beds** added during the quarter
- ✓ **66 beds at Patna and 52 beds added at Lucknow**
- ✓ **73 ICU beds** operationalized in Q2 FY25
- ✓ Announced signing of O&M agreement to operate and manage a **~750 beds** super-specialty hospital in Pitampura Delhi



Attract Best Talent

- ✓ **25 Doctors on-boarded in** Q2 FY25 and 52 Doctors in H1 FY25 across Matured and Developing facility
- ✓ **Strengthening** clinical capability through talent additions
- ✓ **675+ total workforce**; added during the quarter



Enhance Capabilities

- ✓ Magnetom Vida **MRI System** with Paradigm Generator and **Da Vinci Xi robotic system** operationalized at Gurugram in Q2 FY25
- ✓ **Surgical Robot Da Vinci Xi** introduced at Lucknow
- ✓ **High Dose Radiopharmaceutical Therapy Ward** (First of its kind in Medanta) has become functional at Nuclear Medicine Department, Medanta, Lucknow



Continuity of Care

- ✓ Launched **Medanta Clinics** at Gurugram and Ranchi
- ✓ Overall **Medanta Lab network of 200+ touch points** comprising of 10 Labs, 9 COCO and 176 FOFO
- ✓ **7 Pharmacies and network of ~40** neighbourhood primary care clinics in Gurugram, Delhi and Lucknow

Q2 FY2025 clinical achievements


Continuing the legacy of clinical excellence

- Medanta Gurugram **performed its first CAR-T Cell therapy**, an advanced cancer treatment that harnesses the power of the patient's own immune system to fight cancer
- Medanta Gurugram achieves significant milestone of completing **3,000 kidney transplants**
- Medanta Lucknow completes **100 breast cancer surgeries**
- Medanta Gurugram doctors successfully performed **bilateral lung transplant** in a patient with ILD and complex autoimmune condition
- Splenectomy and BMT at Medanta Lucknow save life of 9-year-old thalassemic boy presenting with alloimmunisation **deemed inoperable** in other centres
- Medanta Gurugram doctors uses **minimally invasive unique approach to treat rare heart condition** Idiopathic Chylopericardium
- Complex and **severe genetic disorder Wiskott Aldrich Syndrome cured** at Medanta Gurugram using half-match stem cell transplant
- **Emerging technology Genuclate Artery Embolisation** used at Medanta Gurugram for knee osteoarthritis in 72-yr-old with comorbidities
- Medanta Patna saves infant through early detection of Trichohepatoenteric Syndrome - one of **world's rarest disorders**


Key operating metrics: Revenue and profitability

Revenue increased by 12.7%, EBITDA grew by 5.5% y-o-y


Total Income (INR million)




EBITDA (INR million and margin %)



Profit before tax (INR million and margin%)




Profit after tax (INR million and margin %)




Key operating metrics: Volumes, occupancies, ALOS

Occupied bed days increased by 9% y-o-y on the increased bed capacity


Average census and occupied beds




ALOS (days)



IPD volumes ('000)




OPD volumes ('000)




Key operating metrics: ARPOB and revenue mix

ARPOB growth driven by improved realization


ARPOB* (INR)




IPD Revenue mix by payor category **



Domestic and international revenue breakdown



IPD vs OPD revenue breakdown




*ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days

** IPD revenue mix by payor category is based on payment type


Diverse revenue¹ mix

Significant contribution from complex specialties

Revenue mix by specialty Q2 FY24



Revenue mix by specialty Q2 FY25



Heart Digestive Cancer³ Neuro Kidney & Urology Internal Medicine Ortho Liver Transplant Others

Notes:


1. Revenue from healthcare services excludes pharmacy revenue and other income
2. Revenue breakdowns are provided as per internal MIS at the Company's consolidated level
3. Cancer includes medical oncology, radiation oncology, head & neck surgery, bone marrow transplant and breast surgery

Growth seen in both matured and developing hospitals


Matured hospitals continues to deliver strong growth

Matured hospitals - Over 6 years


Total Income (INR million)




EBITDA (INR million and margin %)



Occupied Bed Days




ARPOB* (INR)




Developing hospitals - Less than 6 years


Total Income (INR million)




EBITDA (INR million and margin %)



Occupied Bed Days



ARPOB* (INR)



*ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days

Q2 FY2025 performance summary

Well capitalized balance sheet to drive future expansion plans and growth

INR million	FY2023	FY2024	H1 FY2025
Gross Debt	8,422	4,193	3,019
Cash and Cash Equivalents	13,114	11,913	10,205
Net Debt / (Net Cash)	(4,692)	(7,720)	(7,186)
Total Equity	24,282	29,056	31,427
Net Debt to Equity (x)	-	-	-
Net Cash flow from Operations	6,445	6,121	2,993
EBITDA	6,771	8,737	4,548
EBITDA to Cash Flow Conversion (%)	95%	70%	66%
Net Debt to EBITDA (x)	-	-	-

Key Highlights

- Debt repayment of ~ INR 1,174 million during H1 FY2025
- Net Cash surplus of INR 7,186 million at the end of 30th September, 2024
- In H1 FY2025, INR 3,702 million of capex incurred including INR 1,314 million related to acquisition of Land in Mumbai
- Well capitalized balance sheet to drive future expansion plans and growth


02

Medanta Poised to Deliver Sustainable Growth

Values based growth you can be proud of

Medanta is well placed to deliver sustainable growth...

...while maintaining its core values of patient centric care and clinical leadership and quality



Noida hospital construction update

97% superstructure complete; MEP work in progress. Expected to commence operations in Q1 FY26

- Project situated in sector 50 Noida, **close proximity to metro station**
- Greenfield project, with bed capacity of **550 beds**
- Construction started **in September 2022**
- **Mechanical Electrical and Plumbing work in progress**
- Hospital expected to commence operations with **300 beds** in Q1 FY26
- Designed for highest patient care, the project has received **pre-certification of Green Building Certification** under IGBC Green Healthcare Facilities Rating System by CII-Indian Green Building Council



Pitampura, New Delhi : ~750 bed in partnership with Society

Expanding into the high-growth, densely populated micro markets of Northwest and West Delhi

Super specialty hospital in North West Delhi



- Medanta has signed an Operations and Management Agreement with Society to operate and manage a **~750 bed super speciality hospital at Pitampura, New Delhi**
- The hospital will be located on a **7-acre site in Pitampura**, with a total built-up area of 7.6 Lakh sq.ft excluding the basement
- The hospital is to be **jointly built** by Medanta and Society **over next ~4 years**, subject to necessary statutory and customary approvals
- Medanta is expected to incur a **project capex of ~INR 600 cr**, to be funded by a combination of internal accruals and debt financing



Medanta to enter Mumbai market with a state-of-the-art, 500+ bedded super-specialty hospital at Oshiwara, Mumbai



**The image is for representation purpose only*

- ✓ The Company has bought 8,859 sq.meters of land in Oshiwara from MHADA for an amount of INR 125.11 crores in a public auction
- ✓ Medanta has paid INR 125.11 crores and executed lease deed. In addition, the company need to purchase additional FSI from MHADA
- ✓ The facility is expected to have a capacity of 500+ beds and will set new benchmarks in healthcare delivery, providing world-class medical services and advanced treatment options to the residents of Mumbai and surrounding regions
- ✓ The project cost including Land and FSI purchase is estimated to be in the range of INR 1,000-1,200 crores

Tender Won

**INR 125.11 crores
Bid Amount Paid**

**Lease Agreement
Signed**

**Barricading and
Security Ongoing**

South Delhi and Indore project update

Project delayed due to ongoing challenges

Super specialty hospital in South Delhi



- **~400-bed super specialty** hospital in South Delhi
- DLF and Medanta will contribute equity in equal proportion (50:50)
- **Medanta will run the hospital** and have operational control; DLF will be a strategic investor
- SPV named **“GHL Hospital Limited”** was formed in December 2023
- Site survey complete, soil testing to be initiated. All development halted due to GRAP in Delhi and tree felling restrictions

Asset light hospital partnership in Indore



- Site identified in prominent location on MR 10 road
- O&M project with partner building ‘warm shell’
- Total operational area of **~5 lakh sq. ft.**
- Plan to build **300 beds including 100+ critical care beds**
- Will cover all major super specialties
- **Ongoing Case Status:** The case has been filed between the erstwhile buyer and seller.
- The High Court has ruled in favor of the erstwhile buyer and cleared the property sale to our partner. However, the appellant has filed a review petition

Medanta Clinic at Golf Course Road, Gurugram



- Clinic situated on Gold Course road
- Total area of 19,000 sq.ft, with Ground + 3 Floors of construction
- Services to include 8 Day Care beds, Endoscopy Suites, Dermatology and Aesthetic Clinics, Dental, Executive Health Checks and OPD Consults
- Pathology and Radiology (MRI, CT, X-Ray, MAMO, DEXA, OPG)
- **OPD started in October 2024 and Day Care procedures expected to start in Q3 FY2025**

Medanta Clinic at Ranchi



- Clinic situated Atal Smriti Vendor Market Kutchery Road, Ranchi
- Total area of 9,629 sq.ft, with Ground + 3 Floors of construction
- Services to include OPD consultations and health checks
- Pathology and Radiology (MAMO, X Ray, DEXA, Dental)
- **OPD started in September 2024, Diagnostics and Executive Health Check to start in December 2024**

Completing the Medanta Gurugram campus

Establishing World Class Medical College and Guest House for Out of City Patients

Medanta Medical College



- Establish a **world-class, future-ready Medical College** in Gurugram which would provide high quality education of global standards
- Documentation process of obtaining necessary regulatory approvals from the State and National Medical Council (NMC) has been initiated
- Architectural drawing preparation has commenced

Medanta Guest House




- To ensure continuity of care for our patients, **Medanta to construct a service apartments / guest house** on the “Medanta-The Medicity” Gurugram campus
- This project with an investment of ~INR 250 crores will cater to the growing demand from international as well as out of town domestic patients for comprehensive healthcare and allied services
- This facility will also help us optimize length of stay in our Gurugram hospital by providing continuity of care in a safe and secure out of hospital environment

On-going expansion projects

Planned bed capacity addition; well positioned to drive near term growth


Number of installed beds



- ❖ **Gurugram:** In Q1 FY25, Inaugurated dedicated floor for mother and child with 49 beds (including 25+ dedicated neonatal beds)
- ❖ **Lucknow:** Total 98 beds added in March 2024, 52 total beds added in Q2 FY25
- ❖ **Patna:** 18 dialysis beds added in Q1 FY25 and 66 total beds including 28 census beds, 21 Dialysis and 17 Chemo beds added in Q2 FY25
- ❖ **Noida with total capacity of 550 beds:** 300 beds planned expected to operationalise by Q1 FY26
- ❖ **South Delhi:** Announced 400 bed in partnership with DLF. The project is delayed due to tree felling restrictions
- ❖ **Indore:** Announced 300 bed in partnership with real estate partner. Project delayed due to ongoing case between erstwhile owner and seller
- ❖ **Mumbai:** Land acquired in Mumbai with a potential to build 500+ bed post regulatory and customary approvals
- ❖ **Pitampura, New Delhi:** Signed O&M Agreement to operate and manage a ~750 bed super speciality hospital at Pitampura, New Delhi

Capex plan next 5 years

Total capex of INR ~2,800 crores planned for next 5 years for ~2,900 bed addition



- ❖ In H1 FY2025, **INR 370 crores of capex incurred** including INR 131 crores related to acquisition of Land in Mumbai
- ❖ **Maintenance capex and capex on bed addition at Lucknow and Patna estimated at ~470 crores** to be incurred over next three years
- ❖ **Project capex for bed capacity addition estimated at INR ~2,800 crores**, to be funded by combination of Debt funding and internal accruals

03

About Us

Medanta was founded to bring a new type of healthcare to India...



... the human side of healthcare

Healthcare is never only about science. It is also about the **art of medicine** – the **human connection**, putting the **patient first**, **collaboration**, the personal acts of **empathy** and the **values** that guide our decision making.



At Medanta we have built an institution to match the highest benchmarks of excellence globally. We have created an ecosystem of excellence that encompasses world-leading clinicians, state-of-the-art equipment, best-in-class infrastructure, and a strong emphasis on research and innovation.


Medanta's patient-first approach allows teams of super-specialist doctors to collaborate seamlessly and arrive at the best-possible treatment customized for each patient in line with our guiding philosophy 'Har Ek Jaan Anmol', meaning 'Every Life is Invaluable'



Dr. Naresh Trehan
CMD & Chief Cardiac Surgeon, Medanta

Growth from a single flagship hospital in Gurgaon...

...to a network of 5 high quality hospitals across north India



* Carlyle Group (Anant Investments) exited completely in the IPO

Infrastructure and technology

Built to deliver the most complex care

Network of **5** multi-speciality hospitals

1 under construction hospital

6 clinics across **4** cities

Over **3,000*** beds expanding to **~3,500+** by FY2026E

80+ operation theatres
700+ ICU beds

Facilities for **30+** medical specialties

4.7 million sq. ft. of built-up area with additional land for expansion

High quality clinical talent

Full time doctors; team based care

1,750+ doctors*

6,800+ nurses and paramedics*

11,300+ full-time and retainer employees*

Patients treated

Seen as the 'last stop' in healthcare

2 million+ patients treated annually

1,00,000+ procedures annually

Patients treated from over **130** countries

Awards and accreditations

National and international recognition

Medanta - The Medicity, Gurgaon rated **Best Private Hospital in India Five years in Row** by Newsweek

Medanta Gurgaon **reaccredited 4 times with JCI**; Gurgaon, Lucknow, Patna, Indore, Ranchi are **NABH accredited**



From our flagship Medicity campus in Gurgaon, we have grown to ~3,008 beds across 5 cities

Largest private hospital beds in operation under one roof in Delhi (NCR), Uttar Pradesh and Bihar



GURGAON

1,440 beds; 316 ICU beds



LUCKNOW

751 beds; 202 ICU beds (950 planned)



PATNA

442 beds; 112 ICU beds (650 planned)



INDORE

175 beds; 53 ICU beds



RANCHI

200 beds; 54 ICU beds



NOIDA

550 total beds (under construction)

Embracing a new era and redefining our purpose

MISSION

Our mission is to deliver world class, patient centric, integrated and affordable healthcare through a dynamic institution that focuses on the development of people and knowledge

Core Values



Patient centric care: Foster a culture where every one of us is committed to care for patients and their caregivers



Leadership and quality: Commit to delivering excellence in everything we do through exemplary action and behaviour




Integrity and courage: Maintain the highest ethical standards by putting the patient first and demonstrating the courage to do what is right



Collaboration, learning and innovation: Promote teamwork and collaboration, welcome change and creativity, encourage innovation

The Medanta Model of Care

Delivering the highest quality of medicine with care and compassion



What it means for patients and caregivers?

- Super specialized doctors provide the highest quality of care through a team based integrated approach
- A safe and friendly healing environment with a patient-centric design in all clinical areas and public spaces
- Availability of the most advanced, innovative equipment and technology to enable the most complex diagnostics and treatment
- Doctors who take ownership and responsibility
- Respect-based processes for patients and their families

Annexure: Profit and Loss statement

INR million	Half Year End			Quarter				
	H1 FY24	H1 FY25	Y-o-Y Growth %	Q2 FY24	Q1 FY25	Q2 FY25	Y-o-Y Growth %	Q-o-Q Growth %
Revenue from operations	16,300	18,176	11.5%	8,504	8,611	9,566	12.5%	11.1%
Other income	292	401	37.7%	142	219	182	27.9%	(16.9)%
Total income	16,592	18,578	12.0%	8,647	8,830	9,748	12.7%	10.4%
Cost of materials consumed	3,750	4,368	16.5%	1,936	2,089	2,280	17.8%	9.2%
Employee benefits expense	5,690	6,563	15.3%	2,912	3,197	3,366	15.6%	5.3%
Other expenses	2,823	3,099	9.8%	1,463	1,462	1,637	11.8%	11.9%
EBITDA	4,329	4,548	5.0%	2,336	2,082	2,465	5.5%	18.4%
EBITDA Margins %	26.1%	24.5%	(162) bps	27.0%	23.6%	25.3%	(173) bps	170 bps
Finance costs	380	340	(10.7)%	201	180	160	(20.5)%	(11.1)%
Depreciation and amortisation expense	833	960	15.3%	429	466	494	15.2%	6.0%
Profit before tax	3,116	3,248	4.2%	1,706	1,437	1,811	6.2%	26.1%
Tax expenses	845	877	3.8%	454	374	503	10.6%	34.5%
Profit after tax	2,272	2,371	4.4%	1,252	1,063	1,308	4.5%	23.1%

Note: Previous period figures have been regrouped/reclassified to conform to the current period's classification

Annexure: Operational parameters

Key metrics	Half Year End			Quarter				
	H1 FY24	H1 FY25	Y-o-Y Growth %	Q2 FY24	Q1 FY25	Q2 FY25	Y-o-Y Growth %	Q-o-Q Growth %
Total Beds	2,725	3,008	10.4%	2,725	2,890	3,008	10.4%	4.1%
Average Census Beds	2,223	2,400	8.0%	2,223	2,354	2,446	10.0%	3.9%
Average Occupied Bed Days	250,066	270,636	8.2%	132,565	126,072	144,564	9.1%	14.7%
Average Occupancy Rate %	67.5%	61.6%	0.2%	64.9%	58.8%	64.3%	(0.9)%	9.3%
ARPOB (INR)*	62,011	63,023	1.6%	61,003	64,035	62,140	1.9%	(3.0)%
ALOS (days)	3.17	3.13	(1.2)%	3.19	3.05	3.20	0.2%	4.8%
In-Patient Volumes	78,934	86,462	9.5%	41,506	41,293	45,169	8.8%	9.4%
Out-Patient Volumes	1,384,907	1,499,087	8.2%	727,728	723,692	775,395	6.6%	7.1%

*ARPOB is calculated on Hospital Revenues excluding Pharmacy and Other Income divided by Occupied bed days

Abbreviations

- INR : Indian Rupee
- NABH : National Accreditation Board for Hospitals & Healthcare Providers
- NABL : National Accreditation Board for Testing and Calibration Laboratories
- JCI : Joint Commission International
- OPD : Out-Patient Department
- IPD : In Patient Department
- ICU : Intensive Care Unit
- Mn : Million
- ARPOB : Average Revenue Per Occupied Bed
- ALOS : Average Length of Stay
- EBITDA: EBITDA represents Profit before tax after adding back finance costs and depreciation and amortization of the relevant year/period
- EBITDA Margin : EBITDA divided by Total Income in percentage
- PAT : Profit After Tax
- NCR : National Capital Region

Definitions

- Bed Capacity / Installed Beds : Total Bed available in the hospital (including census (bed available for mid-night occupancy) and non-census beds (all other bed available other than census beds, i.e., day-care beds).
- Occupied beds : Total Count of patients at midnight at each day
- Average Occupancy Levels : (Total Occupied beds/Total census beds) i.e. Excluding day Care bed, Emergency, Dialysis beds, Pre & post catherization & Observation room
- ICU Beds: No of ICU Beds available in the hospital out of census beds
- Total Income : Revenue from Operations + Other Income
- ARPOB : Income from Health Care Services excluding Pharmacy and Other Income revenue divided by occupied bed days
- ALOS : Average number of days spent by admitted inpatients
- Revenue mix by Payment Type, i.e. Cash, TPA,CGHS, ECHS, PSU others.

About Medanta

Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third- and fourth-highest civilian awards in India, and the Dr. B.C. Roy Award in recognition of his distinguished contribution to medicine.

Global Health Limited (the “Company”) is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, with key specialties cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology, according to the report titled “An assessment of the healthcare delivery market in India, September 2022” by CRISIL Limited.

Under the “Medanta” brand, the Company has a network of five hospitals currently in operation (Gurgaon, Indore, Ranchi, Lucknow, and Patna). Spanning an area of 4.7 million sq. ft., its operational hospitals have 3,008 installed beds as on September 30, 2024. It also has one hospital under-construction in Noida. The Company provides healthcare services in over 30 medical specialties and engages over 1,750+ doctors led by highly experienced department heads.

Contact Details

Ravi Gothwal –
Head of Investor Relations



+91 95996 55711



ravi.gothwal@medanta.org



Corporate Office

Medanta; The Medicity

CH Baktawar Singh Rd, Medicity, Islampur Colony, Sector 38,
Gurgaon, Haryana 122001



For further information, please visit our website:

<https://www.medanta.org/>